the Hypertrophic Scar Prevention of BMT101.

An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of BMT 101 Administration for the Prevention of Hypertrophic Scar

An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial

As a comparative evaluation between the control group (untreated-control) and the study group (treatment) within a subject, it was decided to assign ten subjects to each of the three dose groups.

Inclusion Criteria:

• male and female adults aged 19-55 years
• Those who plan to undergo a revision surgery to remove hypertrophic scar resulted from a previous abdominal surgery
• Those who voluntarily signed the written consent and agreed to participate in the study.

Exclusion Criteria:

• Pregnant or lactating women
• Those with clinically significant systemic disease (e.g. diabetes, hematologic disease, allergic or immunogenic systemic skin disease)